177 related articles for article (PubMed ID: 33616086)
1. FcγRIIB is a T cell checkpoint in antitumor immunity.
Farley CR; Morris AB; Tariq M; Bennion KB; Potdar S; Kudchadkar R; Lowe MC; Ford ML
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33616086
[TBL] [Abstract][Full Text] [Related]
2. Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8
Morris AB; Farley CR; Pinelli DF; Adams LE; Cragg MS; Boss JM; Scharer CD; Fribourg M; Cravedi P; Heeger PS; Ford ML
Immunity; 2020 Jan; 52(1):136-150.e6. PubMed ID: 31940267
[TBL] [Abstract][Full Text] [Related]
3. FcγRIIB expressed on CD8
Bennion KB; Tariq M; Wyatt MM; Duneton C; Baecher KM; Paulos CM; Kudchadkar RR; Lowe MC; Ford ML
Sci Transl Med; 2023 Aug; 15(710):eadd1868. PubMed ID: 37611081
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
5. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
6. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
8. CXCR6 is required for antitumor efficacy of intratumoral CD8
Wang B; Wang Y; Sun X; Deng G; Huang W; Wu X; Gu Y; Tian Z; Fan Z; Xu Q; Chen H; Sun Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462326
[TBL] [Abstract][Full Text] [Related]
9. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
[TBL] [Abstract][Full Text] [Related]
10. Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity.
Alvarez Arias DA; Kim HJ; Zhou P; Holderried TA; Wang X; Dranoff G; Cantor H
Cancer Immunol Res; 2014 Mar; 2(3):207-16. PubMed ID: 24778317
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
12. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
13. Memory T cell-mediated rejection is mitigated by FcγRIIB expression on CD8
Morris AB; Pinelli DF; Liu D; Wagener M; Ford ML
Am J Transplant; 2020 Aug; 20(8):2206-2215. PubMed ID: 32154641
[TBL] [Abstract][Full Text] [Related]
14. Suppression of T-cell expansion by melanoma is exerted on resting cells.
Russ AJ; Wentworth L; Xu K; Rakhmilevich A; Seroogy CM; Sondel PM; Suresh M; Cho CS
Ann Surg Oncol; 2011 Dec; 18(13):3848-57. PubMed ID: 21465311
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
16. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
19. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
20. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]